Articles Dulaglutide and cardiovascular outcomes in type 2 diabetes REWIND a doubleblind randomised placebocontrolled trial

[Articles] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

21:47 EDT 9 Jun 2019 | The Lancet

Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.

More From BioPortfolio on "[Articles] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial"